Can AI chatbots master the science of dietary balance?

FHS
January 9, 2025
11:02 pm

Discover how AI chatbots are reshaping weight-loss planning with precision and variety, yet face challenges in balancing macronutrients for optimal health.

Novartis to seek approvals in two rare kidney diseases after positive Phase 3 trials

Novartis is building out its rare kidney disease portfolio with two batches of Phase 3 data at the European Renal Association conference, touting positive results

May 26, 2024

Second-generation mosquito nets prevented 13 million malaria cases in large pilot programs

The fight against malaria is a test of human intelligence against mosquitoes — and so far, our minuscule winged enemy is winning. But new results

April 17, 2024

Merrimack to dissolve after recording $225M milestone; Cogent’s $225M placement

Plus, news about Larimar Therapeutics, Metagenomi, NextPoint Therapeutics, MeiraGTx, Codexis, Invitae, Immunome and BioXcel Therapeutics: Ipsen to pay $225M to Merrimack Pharmaceuticals: The milestone payout

February 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.